1. Home
  2. TGLS vs DMRA Comparison

TGLS vs DMRA Comparison

Compare TGLS & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$37.67

Market Cap

1.6B

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

SELL

Current Price

$18.80

Market Cap

1.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TGLS
DMRA
Founded
1984
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
TGLS
DMRA
Price
$37.67
$18.80
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
★ $55.75
$46.89
AVG Volume (30 Days)
333.1K
★ 669.9K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 1.63%
N/A
EPS Growth
N/A
★ 121.48
EPS
★ 1.27
N/A
Revenue
★ $370,984,000.00
N/A
Revenue This Year
$12.44
N/A
Revenue Next Year
$11.39
N/A
P/E Ratio
$28.95
★ N/A
Revenue Growth
★ 17.98
N/A
52 Week Low
$34.05
$16.50
52 Week High
$63.46
$34.89

Technical Indicators

Market Signals
Indicator
TGLS
DMRA
Relative Strength Index (RSI) 51.76 33.52
Support Level $37.43 $18.73
Resistance Level $46.99 $26.76
Average True Range (ATR) 1.34 1.35
MACD 0.43 0.08
Stochastic Oscillator 78.08 22.39

Price Performance

Historical Comparison
TGLS
DMRA

About TGLS Tecnoglass Inc.

Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: